Marshall Wace’s Acumen Pharmaceuticals ABOS Stock Holding History

Marshall Wace’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$455K	Buy	192,889 +171,982	+823%	+$439K	﹤0.01%	2491
2025 Q4	$44.1K	Buy	+20,907	New	+$41.5K	﹤0.01%	2785
2025 Q3	–	Sell	-137,943	Closed	-$160K	–	2835
2025 Q2	$160K	Buy	+137,943	New	+$148K	﹤0.01%	2493
2024 Q2	–	Sell	-89,707	Closed	-$363K	–	2486
2024 Q1	$363K	Buy	+89,707	New	+$338K	﹤0.01%	2046
2023 Q4	–	Sell	-25,492	Closed	-$106K	–	2113
2023 Q3	$106K	Buy	+25,492	New	+$157K	﹤0.01%	2043
2022 Q3	–	Sell	-18,808	Closed	-$89K	–	3274
2022 Q2	$89K	Sell	18,808 -14,017	-43%	-$52.7K	﹤0.01%	3290
2022 Q1	$129K	Sell	32,825 -123,425	-79%	-$672K	﹤0.01%	3169
2021 Q4	$1.06M	Hold	156,250	–	–	﹤0.01%	2446
2021 Q3	$2.32M	Buy	+156,250	New	+$2.6M	0.01%	1447

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Marshall Wace's ABOS Position: Q1 2026 in Review

Marshall Wace increased its Acumen Pharmaceuticals (ABOS) stake by 823% in Q1 2026, buying an estimated $439K and bringing the position to 192,889 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #2491.

Marshall Wace first reported a position in ABOS in Q3 2021 and has held it in 9 quarters since. The position peaked at $2.32M in Q3 2021. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

Marshall Wace held 192,889 shares of Acumen Pharmaceuticals worth $455K as of Q1 2026.
Marshall Wace bought 171,982 Acumen Pharmaceuticals shares in Q1 2026, an estimated $439K.
Acumen Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2491 holding.
Marshall Wace first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 9 quarters since.
Marshall Wace's Acumen Pharmaceuticals position peaked at $2.32M in Q3 2021.
84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.